BG61419B2 - Производни на карбазолил-(4)-окси-пропаноламина,метод за получаването им и лекарствено средство,съдържащо тези съединения - Google Patents

Производни на карбазолил-(4)-окси-пропаноламина,метод за получаването им и лекарствено средство,съдържащо тези съединения Download PDF

Info

Publication number
BG61419B2
BG61419B2 BG98612A BG9861294A BG61419B2 BG 61419 B2 BG61419 B2 BG 61419B2 BG 98612 A BG98612 A BG 98612A BG 9861294 A BG9861294 A BG 9861294A BG 61419 B2 BG61419 B2 BG 61419B2
Authority
BG
Bulgaria
Prior art keywords
group
formula
carbazolyl
oxy
compound
Prior art date
Application number
BG98612A
Other languages
Bulgarian (bg)
English (en)
Inventor
Fritz Wiedemann
Wolfgang Kampe
Max Thiel
Gisbert Sponer
Egon Roesch
Karl Dietmann
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6036838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG61419(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of BG61419B2 publication Critical patent/BG61419B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG98612A 1978-04-13 1994-02-28 Производни на карбазолил-(4)-окси-пропаноламина,метод за получаването им и лекарствено средство,съдържащо тези съединения BG61419B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
BG61419B2 true BG61419B2 (bg) 1997-07-31

Family

ID=6036838

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98612A BG61419B2 (bg) 1978-04-13 1994-02-28 Производни на карбазолил-(4)-окси-пропаноламина,метод за получаването им и лекарствено средство,съдържащо тези съединения

Country Status (23)

Country Link
US (1) US4503067A (fr)
EP (1) EP0004920B1 (fr)
JP (2) JPS54157558A (fr)
AT (1) AT375639B (fr)
AU (1) AU522975B2 (fr)
BG (1) BG61419B2 (fr)
CA (1) CA1129416A (fr)
CS (2) CS227007B2 (fr)
DD (1) DD143607A5 (fr)
DE (2) DE2815926A1 (fr)
DK (1) DK154555C (fr)
ES (1) ES479396A1 (fr)
FI (1) FI70406C (fr)
HK (1) HK2385A (fr)
HU (1) HU179433B (fr)
IL (1) IL57020A (fr)
LT (1) LT2628B (fr)
LU (1) LU88320I2 (fr)
MX (1) MX9203380A (fr)
NL (1) NL930110I2 (fr)
SG (1) SG52284G (fr)
SU (1) SU810079A3 (fr)
ZA (1) ZA791732B (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131146A1 (de) * 1981-08-06 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
WO1994020096A1 (fr) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Procede d'utilisation de carbazolyle-(4)-oxypropanolamine pour inhiber la proliferation de cellules de muscles lisses
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE19628335A1 (de) * 1996-07-13 1998-01-15 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
US6096777A (en) * 1996-08-23 2000-08-01 Boehringer Mannheim Pharmaceuticals Corporation Method for inhibiting the expression of Fas
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
US5808080A (en) 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
PL332638A1 (en) * 1996-10-09 1999-09-27 Boehringer Mannheim Pharm Corp Method of inhibiting stress-activated proteinous kinases
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
EP0893440A1 (fr) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Une modification thermodynamique stabilisée de 1-(4-carbazolyloxy)-3[2-(2-methoxyphenoxy)ethylamino]- 2-propanole, un procédé pour sa préparation et une composition pharmaceutique qui la contient
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
NZ504418A (en) * 1997-11-12 2003-02-28 Boehringer Mannheim Pharm Corp Delayed release oral dosage form of carvedilol
HU227441B1 (en) * 1997-11-24 2011-06-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing carvedilol, enantiomers and salts thereof
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
KR100520589B1 (ko) * 1998-04-09 2005-10-10 로쉐 디아그노스틱스 게엠베하 카베딜롤-갈레누스 제제
EP0968714A1 (fr) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Procédé de préparation de compositions pharmaceutiques à dissolution rapide contenant des agents actifs difficilement solubles
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
WO2001035958A1 (fr) * 1999-11-15 2001-05-25 Smithkline Beecham Corporation Methane-sulfonate de carvedilol
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
JP2003528914A (ja) * 2000-04-03 2003-09-30 エフ．ホフマン−ラ ロシュ アーゲー カルベジロールの濃縮溶液
DK174645B1 (da) * 2000-05-18 2003-08-04 Gea Farmaceutisk Fabrik As Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
EP1655285A1 (fr) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Procédé de préparation d'une forme crystalline de carvedilol (forme II)
JP2004501191A (ja) * 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20050009897A1 (en) * 2001-04-02 2005-01-13 Karen Anderson Method of treatment
IN191028B (fr) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
ATE328595T1 (de) * 2001-07-13 2006-06-15 Smithkline Beecham Corp Carvedilolpolymorph
WO2003017046A2 (fr) * 2001-08-14 2003-02-27 Variant Holdings, Llc. Systeme de commercialisation de biens et de services utilisant des installations centrales et distantes informatisees
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (fr) 2001-09-21 2015-12-23 Egalet Ltd. Systeme de liberation a base de polymere
RU2308449C2 (ru) * 2001-09-28 2007-10-20 Ф.Хоффманн-Ля Рош Аг Псевдополиморфные формы карведилола
WO2003028718A1 (fr) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Nouvelles formulations de carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003059807A2 (fr) 2002-01-15 2003-07-24 Teva Pharmaceutical Industries Ltd. Corps solides cristallins de carvedilol, et leurs procedes d'elaboration
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
CA2483054A1 (fr) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Monocitrate monohydrate de carvedilol
WO2003092626A2 (fr) * 2002-05-03 2003-11-13 Smithkline Beecham Pharmco Puerto Rico, Inc. Solvate de carvedilol pharmasolve
EP1501500A2 (fr) * 2002-05-03 2005-02-02 SmithKline Beecham Pharmco Puerto Rico, Inc. Formulations de carvedilol
CN101898995B (zh) * 2002-06-27 2013-05-01 史密斯克莱·比奇曼（科克）有限公司 卡维地洛磷酸盐和/或其溶剂合物相应的组合物和/或治疗方法
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
US20060013877A1 (en) * 2002-07-22 2006-01-19 Nanohybrid Co., Ltd. Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
SK285547B6 (sk) * 2002-11-08 2007-03-01 Zentiva, A. S. Spôsob prípravy Carvedilolu
US7468442B2 (en) * 2003-04-21 2008-12-23 Matrix Laboratories Ltd. Process for the preparation of carvedilol form-II
CN1812983A (zh) * 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
US7482471B2 (en) * 2003-06-20 2009-01-27 Sun Pharmaceutical Industries Limited Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
EP1686967A4 (fr) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Base libre de carvedilol, ses sels, formes anhydres ou solvats, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et methodes de traitement ou d'administration
EP1691789B1 (fr) 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Base libre de carvedilol, ses sels, formes anhydres ou solvates, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et procedes de traitement ou d'administration
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
US20070191456A1 (en) * 2004-04-22 2007-08-16 Tarur Venkatasubramanian R Novel process for the preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
JP2008521805A (ja) * 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
PL1838670T3 (pl) * 2004-12-09 2010-03-31 Zach System Spa Sposób wytwarzania karwedilolu i jego enancjomerów
US20070027202A1 (en) * 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
EP1781611A1 (fr) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Formes cristallines du carvedilol et leurs procedes de preparation
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AU2006300877A1 (en) 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pSTAT3/IL-6 inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP1948599A1 (fr) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Procede de preparation de sel hemicalcique d acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
EP1991527A2 (fr) * 2006-06-28 2008-11-19 Teva Pharmaceutical Industries Ltd Formes polymorphes de carvédilol phosphate
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
WO2008038301A1 (fr) * 2006-09-26 2008-04-03 Morepen Laboratories Limited Procédé pour la préparation de carvédilol
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008070072A2 (fr) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Formes, compositions de carvédilol, et leurs procédés de préparation
WO2008084494A1 (fr) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Nouvelles formes polymorphes de dihydrogénophosphate de carvedilol et procédé de préparation de celles-ci
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CZ302357B6 (cs) * 2007-01-26 2011-03-30 Zentiva, A. S. Zpusob cištení Carvedilolu
WO2008105794A1 (fr) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Procédé de purification du carvédilol ou de ses sels
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (fr) * 2007-05-17 2008-11-27 Wanbury Limited Nouveau procédé économique pour la production de phosphate de carvédilol
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2195292B1 (fr) * 2007-08-21 2013-10-02 Lupin Ltd. Forme amorphe stable de dihydrogène phosphate de carvedilol avec agent stabilisant
WO2009035535A2 (fr) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Procédé de cristallisation de phosphate de carvédilol et produit obtenu par ce procédé
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
US8889728B2 (en) * 2008-03-04 2014-11-18 Lupin Limited Stable pharmaceutical compositions of carvedilol
WO2009115902A1 (fr) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Procédé permettant de préparer du carvedilol par protection silyle d'amine substituée
WO2009115906A2 (fr) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Procédé amélioré pour la préparation du carvédilol impliquant un dérivé d'halohydrine
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
WO2010092589A2 (fr) * 2008-05-26 2010-08-19 Alkem Laboratories Ltd. Procédé de préparation du phosphate de carvédilol amorphe
WO2010089132A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Composition à libération immédiate résistant à une maltraitance par prise d'alcool
EP2445487A2 (fr) 2009-06-24 2012-05-02 Egalet Ltd. Formulations à libération contrôlée
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
CN104080828B (zh) 2011-12-16 2016-05-04 3M创新有限公司 包含环氧乙烷的双失水己糖醇衍生物及其用途
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
US8492426B1 (en) 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
EP2986599A1 (fr) 2013-04-17 2016-02-24 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
CN113372260A (zh) * 2021-07-05 2021-09-10 大连蒙迪科技有限公司 一种卡维地洛杂质的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1834015A (en) * 1929-06-29 1931-12-01 Gen Aniline Works Inc Manufacture of hydroxy carbazoles
DE1152107B (de) * 1956-06-27 1963-08-01 Chem Fab Promonta G M B H Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
BE789072A (fr) * 1971-09-23 1973-03-21 Astra Laekemedel Ab Composes abaissant le taux de lipides du serum et leur obtention
AT336176B (de) * 1971-12-10 1977-04-25 Sandoz Ag Verfahren zur herstellung eines pharmazeutischen praparates
US3975398A (en) * 1973-08-01 1976-08-17 Boehringer Mannheim G.M.B.H. 9-Substituted 3-aminocarbazole compounds
DE2339396C2 (de) * 1973-08-03 1984-06-28 Boehringer Mannheim Gmbh, 6800 Mannheim N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten
DE2424523A1 (de) * 1974-05-21 1975-12-11 Boehringer Mannheim Gmbh Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung
DE2454406A1 (de) * 1974-11-16 1976-05-20 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4076829A (en) * 1974-11-16 1978-02-28 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4152446A (en) * 1974-11-16 1979-05-01 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4115409A (en) * 1975-12-05 1978-09-19 Imperial Chemical Industries Limited Alkanolamine derivatives
GB1508208A (en) * 1975-12-05 1978-04-19 Ici Ltd Amide derivatives

Also Published As

Publication number Publication date
NL930110I1 (nl) 1993-10-18
ATA276279A (de) 1984-01-15
CS420091A3 (en) 1992-04-15
HU179433B (en) 1982-10-28
ZA791732B (en) 1980-05-28
LU88320I2 (de) 1994-05-04
CA1129416A (fr) 1982-08-10
JPS63258416A (ja) 1988-10-25
HK2385A (en) 1985-01-18
IL57020A0 (en) 1979-07-25
NL930110I2 (nl) 1994-12-01
DE2815926A1 (de) 1979-10-18
DK154555C (da) 1989-06-19
SU810079A3 (ru) 1981-02-28
MX9203380A (es) 1992-09-01
ES479396A1 (es) 1980-04-16
FI791142A (fi) 1979-10-14
DK154555B (da) 1988-11-28
AU4582079A (en) 1979-10-18
JPS54157558A (en) 1979-12-12
FI70406C (fi) 1986-09-19
LT2628B (lt) 1994-04-25
EP0004920A1 (fr) 1979-10-31
US4503067A (en) 1985-03-05
IL57020A (en) 1982-07-30
DK141979A (da) 1979-10-14
AT375639B (de) 1984-08-27
SG52284G (en) 1985-03-29
JPH0123462B2 (fr) 1989-05-02
AU522975B2 (en) 1982-07-08
EP0004920B1 (fr) 1981-08-05
CS227007B2 (en) 1984-04-16
DE2960553D1 (en) 1981-11-05
FI70406B (fi) 1986-03-27
DD143607A5 (de) 1980-09-03

Similar Documents

Publication Publication Date Title
BG61419B2 (bg) Производни на карбазолил-(4)-окси-пропаноламина,метод за получаването им и лекарствено средство,съдържащо тези съединения
EP0126449B1 (fr) Aryloxy- et arylthio-hydroxypropyl-pipérazinylacétanilides cardiosélectifs influençant l'entrée de calcium
JP2601008B2 (ja) ナフチルオキサゾリドン誘導体、その製法及びその合成中間体
KR0149508B1 (ko) 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도
US7419974B2 (en) Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same
JPS6215062B2 (fr)
EP0054304B1 (fr) Dérivés de l'alcoylènedioxybenzène, leurs sels d'addition et leur procédé de préparation
EP0034116A2 (fr) N-(3-phénoxy-2-hydroxypropyle)benzimidazole-1-alcanoylamines
US4147869A (en) 3,4-Dihydrocarbostyril derivatives and process for preparing the same
JPH10152460A (ja) ２−アミノ−１−（４−ヒドロキシ−２−メチルフェニル）プロパノール誘導体
JP3467043B2 (ja) ブチルチオ−イソキノリン及びそれの中間体を製造するための方法
JP3492433B2 (ja) ３−（フェニルアルキルアミノアルキルオキシ）−５−フェニルピラゾール−化合物、その製造のための方法及び中間体、及びこれを含有する心臓循環作用薬剤
JPH01151561A (ja) フタラジン化合物、その製造方法、ならびにこの化合物を含有する心血管疾患および腫瘍の治療剤
US4434174A (en) Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines
JPS628115B2 (fr)
JPH0345047B2 (fr)
WO1992020666A1 (fr) Derive de benzothiadiazine
US4321398A (en) Thienyl and benzothienyl-tertiary butylaminophenoxypropanols
WO2000005193A1 (fr) DERIVES DE GUAIACOXYPROPANOLAMINE A ACTIVITE α/β-ADRENOLYTIQUE
CS227047B2 (cs) Způsob výroby derivátů karbazol-4-yloxypropanolaminu
JPS6148821B2 (fr)
JPH0827154A (ja) アザクロマン誘導体及びその用途
FR2555169A2 (fr) Nouveaux (carbethoxy-2 benzalkylamido-4 phenoxyl)-1 amino-3 propanols-2, leurs preparations et leurs utilisations en therapeutique
JPS645036B2 (fr)